SIENNASDAQHealthcare · Medical - Devices

Sientra, Inc.

$0.17-18.69%($-0.04)

TickerSpark Score

62/100

Mixed

100

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SIEN research report →

52-Week Range0% of range

Low $0.16

Current $0.17

High $4.94

Companysientra.com

Sientra, Inc. , a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

CEO: Ronald Menezes
IPO: 2014
Employees: 304
HQ: Santa Barbara, CA, US

Price Chart

-94.38% · this period

Valuation

Market Cap: $2.08M
P/E: -0.02
P/S: 0.02
P/B: -1.52
EV/EBITDA: -0.69
Div Yield: 0.00%

Profitability

Gross Margin: 45.94%
Op Margin: -76.26%
Net Margin: -80.96%
ROE: -366.21%
ROIC: -89.06%

Growth & Income

Revenue: $90.55M · 12.23%
Net Income: $-73,307,000 · -17.26%
EPS: $-10.27 · 6.64%
Op Income: $-69,050,000
FCF YoY: 16.04%

Performance & Tape

52W High: $4.94
52W Low: $0.16
50D MA: $0.57
200D MA: $1.80
Beta: 2.03
Avg Volume: 2.47M

Get TickerSpark's AI analysis on SIEN

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Nov 13, 23	Menezes Ronald	director, officer: President and CEO	other	3,625	$2.57K
Nov 13, 23	Van Hove Caroline F.	director	other	741	$526.11
Sep 7, 23	Bennett Oliver Christian	officer: GC & Chief Compliance Officer	other	2,739	$4.79K
Aug 3, 23	Schmidt Andrew C	officer: Chief Financial Officer	other	561	$2.17K
Jun 15, 23	SCHAISON PHILIPPE	director	other	12,000	$0
Jun 15, 23	FISHER MARY	director	other	12,000	$0
Jun 15, 23	Erenburg Irina	director	other	12,000	$0
Jun 15, 23	Ebersole Nori	director	other	12,000	$0
Jun 15, 23	Casdin Alexander W.	director	other	15,000	$0
Jun 15, 23	Casdin Alexander W.	director	other	0	—

Our SIEN Coverage

View all →

ipo_article

Conexeu Sciences Inc. IPO: What to Know Before It Lists

Conexeu Sciences Inc. (NASDAQ: CNXU) is expected to list on 2026-05-21, with the price range not yet disclosed. The setup is a preclinical regenerative medicine story with no FDA-cleared product yet, so shareholders should watch for pricing, dilution, and how the market values the pipeline risk.

May 20, 2026